Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

Since the proposal of Paul Ehrlich's magic bullet concept over 100 years ago, tremendous
advances have occurred in targeted therapy. From the initial selective antibody, antitoxin to …

Abstract The bisphosphonates ((HO) 2 P (O) CR 1 R 2 P (O)(OH) 2, BPs) were first shown to
inhibit bone resorption in the 1960s, but it was not until 30 years later that a detailed …

Osteonecrosis of the jaw (ONJ) was defined as exposed, necrotic bone in the maxillofacial
region for at least 8 weeks in patients receiving an antiresorptive medication for primary or …

Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-
threatening sequelae and mortality. Osteomyelitis pathogens are bone-attached biofilms …

Medication-related osteonecrosis of the jaw (MRONJ) has emerged as a complication of anti-
resorptive medications. Despite its low incidence rate, this problem has gained attention in …

Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of
antiresorptive medications administered for control of osseous malignancy, osteoporosis, or …

Bone infection results in a complex inflammatory response and bone destruction. A broad
spectrum of bacterial species has been involved for jaw osteomyelitis, hematogenous …

Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a
standardized protocol for the prevention of denosumab induced medication-related …

Advances in the design of potential bone‐selective drugs for the treatment of various bone‐
related diseases are creating exciting new directions for multiple unmet medical needs. For …